COMMUNIQUÉS West-GlobeNewswire

Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase
24/04/2024
CHATHAM, N.J., April 24, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, [...]
LifeMD to Report First Quarter 2024 Financial Results on May 8
24/04/2024
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD) , a leading provider of virtual primary care services, announces that it will report financial results for the three months ended March 31, 2024 [...]
Oruka Therapeutics Expands Leadership Team, Naming Joana Goncalves, MBChB, as Chief Medical Officer
24/04/2024
Dr. Goncalves, former CMO at Cara Therapeutics, joins Oruka as CMO Eugenia Levi, PharmD, former Head of Global Medical Affairs for Cosentyx at Novartis, also joins as VP, Medical Affairs WALTHAM, Mass., April 24, 2024 ( [...]
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
24/04/2024
First non-immunosuppressive therapy for the treatment of IgA nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful results from the [...]
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
24/04/2024
NEW YORK and VIENNA, Austria, April 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today [...]
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
24/04/2024
The BPL-003 Phase 2a trial is an open-label study investigating BPL-003 as both monotherapy and adjunctive to SSRIs in patients with Treatment Resistant Depression. Initial results from the recently completed [...]
PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024
24/04/2024
PETACH TIKVA, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report [...]
Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
24/04/2024
DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly [...]
Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases
24/04/2024
Program is the Product of a Research Collaboration between Biolojic Design and Nektar entered in 2021 TEL AVIV, Israel and SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- Biolojic Design, a biotechnology company that [...]
First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients
24/04/2024
Paper highlights findings on impact of a gluten-containing diet on serologic status in celiac disease BOCA RATON, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave [...]
Treace Medical Named First Medical Device Partner and Official Foot and Ankle Solution Partner of the PPA Tour
24/04/2024
Partnership to help pickleball players of all levels with bunions and related midfoot deformities to “get back on their feet” and out on the court DALLAS and PONTE VEDRA, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- The [...]
LSL Pharma Group Secures $3.8 Million as the Second and Final Tranche of Its Private Placement of Units
24/04/2024
BOUCHERVILLE, Quebec, April 24, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC . (TSXV: LSL) (the " Corporation " or " LSL Pharma "), a Canadian integrated pharmaceutical company, today announced the second and final [...]
Augmedix Launches Industry’s First Fully-Automated, GenAI-Powered, Medical Documentation Product for Emergency Departments
24/04/2024
Following incubation with HCA Healthcare EDs, Augmedix announces the general availability of Augmedix Go in emergency departments SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in [...]
Sharecare to report first quarter fiscal 2024 financial results on Thursday, May 9
24/04/2024
ATLANTA, April 24, 2024 (GLOBE NEWSWIRE) -- Sharecare (Nasdaq: SHCR ), the digital health company that helps people manage all their health in one place, today announced that it will report first quarter fiscal 2024 [...]
Good Supply Cannabis Introduces New Signature ‘Bud Squad’ Products
24/04/2024
TORONTO, April 24, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company today announced the release of new cannabis flower [...]
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
24/04/2024
TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with [...]
ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
24/04/2024
SAN MATEO, Calif. and SINGAPORE, April 24, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the [...]
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
24/04/2024
The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been accepted for poster [...]
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
24/04/2024
The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi ® and Simponi Aria ® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid arthritis Alvotech [...]

Pages